Compared to Estimates, Merit Medical (MMSI) Q4 Earnings: A Look at Key Metrics
Merit Medical (MMSI) reported $355.16 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 9.4%. EPS of $0.93 for the same period compares to $0.81 a year ago.The reported revenue represents a surprise of +0.93% over the Zacks Consensus Estimate of $351.87 million. With the consensus EPS estimate being $0.83, the EPS surprise was +12.05%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Merit Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Cardiovascular- Peripheral Intervention: $140.36 million versus the five-analyst average estimate of $141.35 million. The reported number represents a year-over-year change of +4.6%. Revenue- Cardiovascular- Cardiac Intervention: $95.67 million versus the five-analyst average estimate of $93.51 million. The reported number represents a year-over-year change of +6%. Revenue- Endoscopy: $17.46 million compared to the $17.94 million average estimate based on five analysts. The reported number represents a change of +87.9% year over year. Revenue- Cardiovascular- OEM: $50.44 million versus the five-analyst average estimate of $46.68 million. The reported number represents a year-over-year change of +22.4%. Revenue- Cardiovascular: $337.70 million versus the five-analyst average estimate of $331.43 million. The reported number represents a year-over-year change of +7.1%. Revenue- Cardiovascular- Custom Procedural Solutions: $51.22 million versus the five-analyst average estimate of $49.87 million. The reported number represents a year-over-year change of +3.2%. View all Key Company Metrics for Merit Medical here>>>Shares of Merit Medical have returned -2.2% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Quelle: Zacks
Nachrichten zu Q4 Inc Registered Shs Unitary
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Q4 Inc Registered Shs Unitary
Keine Analysen gefunden.